ArticleKidney international2019
"Permissive AKI" with treatment of heart failure.
Article in Kidney international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Right Heart Function in Cardiorenal Syndrome.Current heart failure reports · 2022Pooled it
- Drowning the kidneys: from fluid overload to physiology-guided fluid management in onco-hematology.Clinical kidney journal · 2026Review
- Renin-angiotensin system inhibitors (RASi) are not nephrotoxic - they protect the kidneys and the heart.Clinical medicine (London, England) · 2026Review
- A new category for understanding the mechanisms of drug-induced kidney injury.Renal failure · 2025Review
- VExUS Protocol Along Cardiorenal Syndrome: An Updated Review.Journal of clinical medicine · 2025Review
- Taboo in cardiology: renin-angiotensin-aldosterone system antagonists worsening renal failure.European heart journal supplements : journal of the European Society of Cardiology · 2024Article
- Moving toward a contemporary classification of drug-induced kidney disease.Critical care (London, England) · 2023Review
- PoCUS in nephrology: a new tool to improve our diagnostic skills.Clinical kidney journal · 2023Review
- Consensus Obtained for the Nephrotoxic Potential of 167 Drugs in Adult Critically Ill Patients Using a Modified Delphi Method.Drug safety · 2022Article
- Kidney Dysfunction After Acute Heart Failure: Is Acute Kidney Disease the New Acute Kidney Injury?Kidney international reports · 2022Article
- How to interpret serum creatinine increases during decongestion.Frontiers in cardiovascular medicine · 2022Review
- Serum creatinine and cystatin C-based estimates of glomerular filtration rate are misleading in acute heart failure.ESC heart failure · 2021Article
- The Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers on Clinical Outcomes of Acute Kidney Disease Patients: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2021Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Renin-angiotensin-aldosterone system inhibitors have proven clinical benefit in management of patients with heart failure with reduced ejection fraction. However, there are no guidelines to manage decline in kidney function that occurs with initiation and titration of renin-angiotensin-aldosterone system agents during management of heart failure. We discuss the complex interplay of kidney function and heart failure in the presence of renin-angiotensin-aldosterone system agents and suggest a clinical algorithm for management of acute decline in kidney function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.